Insulin response to intravenous glucose in patients with anorexia nervosa showing low insulin response to oral glucose. 1994

T Nozaki, and H Tamai, and S Matsubayashi, and G Komaki, and N Kobayashi, and T Nakagawa
Department of Psychosomatic Medicine, Faculty of Medicine, Kyushu University, Fukuoka, Japan.

To investigate the cause of a low insulin secretory response to an oral glucose tolerance test (OGTT) in patients with anorexia nervosa (AN), we performed iv glucose tolerance tests (IVGTT) before and after treatment in 36 anorectic patients who showed low insulin secretion in response to the OGTT. These patients were subdivided into 3 groups by glucose tolerance curves during the OGTT: normal type, blood glucose level peaking 60 min or earlier after oral glucose ingestion; delayed type, blood glucose level peaking 90 min or later after oral glucose; and flat type, peak blood glucose level of 5.56 mmol/L or less after oral glucose. The results showed that the normal and flat type groups had normal glucose and insulin responses to iv glucose. In the delayed type group, in which the longest duration of AN before therapy was found, initial insulin secretion was decreased in response to both oral and iv glucose, indicating diminished pancreatic beta-cell function. After weight gain, this parameter improved significantly in both tests. The rate of glucose disappearance for the IVGTT was lower both before and after weight gain in this subgroup compared to that in normal controls, suggesting insulin resistance. In conclusion, the low insulin response to oral glucose seen in the flat type group may be due to the disturbance of gastrointestinal factors, such as motility. In contrast, the observations suggest that the delayed type group has beta-cell failure corrected by weight gain and has insulin resistance requiring a longer recovery time; these abnormalities are related to the duration of AN.

UI MeSH Term Description Entries
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D007328 Insulin A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1). Iletin,Insulin A Chain,Insulin B Chain,Insulin, Regular,Novolin,Sodium Insulin,Soluble Insulin,Chain, Insulin B,Insulin, Sodium,Insulin, Soluble,Regular Insulin
D007700 Kinetics The rate dynamics in chemical or physical systems.
D001786 Blood Glucose Glucose in blood. Blood Sugar,Glucose, Blood,Sugar, Blood
D001835 Body Weight The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms. Body Weights,Weight, Body,Weights, Body
D005947 Glucose A primary source of energy for living organisms. It is naturally occurring and is found in fruits and other parts of plants in its free state. It is used therapeutically in fluid and nutrient replacement. Dextrose,Anhydrous Dextrose,D-Glucose,Glucose Monohydrate,Glucose, (DL)-Isomer,Glucose, (alpha-D)-Isomer,Glucose, (beta-D)-Isomer,D Glucose,Dextrose, Anhydrous,Monohydrate, Glucose
D005951 Glucose Tolerance Test A test to determine the ability of an individual to maintain HOMEOSTASIS of BLOOD GLUCOSE. It includes measuring blood glucose levels in a fasting state, and at prescribed intervals before and after oral glucose intake (75 or 100 g) or intravenous infusion (0.5 g/kg). Intravenous Glucose Tolerance,Intravenous Glucose Tolerance Test,OGTT,Oral Glucose Tolerance,Oral Glucose Tolerance Test,Glucose Tolerance Tests,Glucose Tolerance, Oral
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000078790 Insulin Secretion Production and release of insulin from PANCREATIC BETA CELLS that primarily occurs in response to elevated BLOOD GLUCOSE levels. Secretion, Insulin
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations

Related Publications

T Nozaki, and H Tamai, and S Matsubayashi, and G Komaki, and N Kobayashi, and T Nakagawa
February 1996, Lancet (London, England),
T Nozaki, and H Tamai, and S Matsubayashi, and G Komaki, and N Kobayashi, and T Nakagawa
October 1964, The Journal of clinical endocrinology and metabolism,
T Nozaki, and H Tamai, and S Matsubayashi, and G Komaki, and N Kobayashi, and T Nakagawa
November 2003, Clinical endocrinology,
T Nozaki, and H Tamai, and S Matsubayashi, and G Komaki, and N Kobayashi, and T Nakagawa
January 1991, Metabolism: clinical and experimental,
T Nozaki, and H Tamai, and S Matsubayashi, and G Komaki, and N Kobayashi, and T Nakagawa
January 1973, Danish medical bulletin,
T Nozaki, and H Tamai, and S Matsubayashi, and G Komaki, and N Kobayashi, and T Nakagawa
January 1990, Zahn-, Mund-, und Kieferheilkunde mit Zentralblatt,
T Nozaki, and H Tamai, and S Matsubayashi, and G Komaki, and N Kobayashi, and T Nakagawa
September 1984, The Journal of clinical endocrinology and metabolism,
T Nozaki, and H Tamai, and S Matsubayashi, and G Komaki, and N Kobayashi, and T Nakagawa
September 1990, Die Quintessenz,
T Nozaki, and H Tamai, and S Matsubayashi, and G Komaki, and N Kobayashi, and T Nakagawa
March 1975, The Journal of clinical endocrinology and metabolism,
T Nozaki, and H Tamai, and S Matsubayashi, and G Komaki, and N Kobayashi, and T Nakagawa
March 1990, Acta psychiatrica Scandinavica,
Copied contents to your clipboard!